Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Setback to online pharmacies: Delhi HC refuses to vacate stay on online sale of medicines

      Setback to online pharmacies: Delhi HC refuses to vacate stay on online sale of medicines

      Farhat Nasim9 Jan 2019 5:05 PM IST
      New Delhi: In a major setback to online pharmacies, the Delhi High court has refused to vacate the stay on online sale of drugs and prescription...
      Sun Pharma recalls lots of Vecuronium Bromide for injection

      Sun Pharma recalls lots of Vecuronium Bromide for injection

      Farhat Nasim9 Jan 2019 10:00 AM IST
      The Vecuronium Bromide for Injection has been found to contain particulate matter identified as glass.New Delhi: Sun Pharmaceutical Industries,...
      Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

      Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

      Farhat Nasim9 Jan 2019 9:15 AM IST
      Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which covers the Sanofi share of the...
      Medical Insurance to refund MRI, pre-operation expenses under mediclaim : Consumer Panel

      Medical Insurance to refund MRI, pre-operation expenses under mediclaim : Consumer Panel

      Farhat Nasim7 Jan 2019 5:29 PM IST
      The insurance company cannot refuse the mediclaim inclusive of MRI and pre-operation expenses simply because the policyholder had spent the amount a...
      Fighting Parkinsons: Medica Hospital to launch new treatment in eastern India

      Fighting Parkinsons: Medica Hospital to launch new treatment in eastern India

      Farhat Nasim7 Jan 2019 12:06 PM IST
      Apomorphine is a highly selective Dopamine receptor emulator, which promotes the release of Dopamine in the brain from the nerve cells, explained Dr...
      Lupin receives FDA approval for Lurasidone Hydrochloride Tablets

      Lupin receives FDA approval for Lurasidone Hydrochloride Tablets

      Farhat Nasim7 Jan 2019 9:45 AM IST
      Lupin's Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg is the generic version of Sunovion Pharmaceuticals, Inc's Latuda...
      Dire need to improve medical infrastructure in country: ICJ India member

      Dire need to improve medical infrastructure in country: ICJ India member

      Farhat Nasim7 Jan 2019 9:30 AM IST
      An Indian member of the International Court of Justice Dalveer Bhandari said there was a "dire need" to make healthcare affordable for all and improve...
      Merck KEYTRUDA receives five new approvals in Japan

      Merck KEYTRUDA receives five new approvals in Japan

      Farhat Nasim7 Jan 2019 9:00 AM IST
      KEYTRUDA is the First Anti-PD-1 Approved in Japan for the First-Line Treatment of Advanced NSCLC as Both Monotherapy and in Combination with...
      Draft of essential diagnostics list out for public comments

      Draft of essential diagnostics list out for public comments

      Farhat Nasim6 Jan 2019 10:00 AM IST
      The National Essential Diagnostics List (EDL) has been drafted after consultation with policymakers, clinicians, laboratories, functionaries in...
      PharmaHopers launches derma franchise category for B2B businesses

      PharmaHopers launches derma franchise category for B2B businesses

      Farhat Nasim6 Jan 2019 9:15 AM IST
      PharmaHopers has a number of dermatology companies listed which are involved in the marketing and manufacturing of derma products like Acne and...
      PMBJP Kendras: Unbranded generic medicines worth Rs 417 crore sold till 2018

      PMBJP Kendras: Unbranded generic medicines worth Rs 417 crore sold till 2018

      Farhat Nasim5 Jan 2019 10:45 AM IST
      Unbranded generic medicines worth Rs 417 crore have been sold through PMBJP Kendras from the inception of the scheme till the end of December 2018,...
      Relief to Foreign Drugmakers: No price cap on innovative drugs for first five years

      Relief to Foreign Drugmakers: No price cap on innovative drugs for first five years

      Farhat Nasim5 Jan 2019 10:44 AM IST
      New Delhi: Through a recent Gazette notice the Central Government has made amendments to the Drugs Prices Control Orders (DPCO),2013 which aim to...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok